<DOC>
	<DOC>NCT00936403</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics (the determination of the concentration of the administered medication in blood over time) and pharmacodynamics (the determination of the effect over time and the duration of action) of a long-acting growth hormone (NNC126-0083) in growth hormone deficient children.</brief_summary>
	<brief_title>A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Confirmed diagnosis of growth hormone insufficiency as defined by two different GH provocation tests, defined as a peak of GH level less than 7ng/ml Prepubertal children Growth hormone replacement treatment for at least three months Evidence of tumour growth or malignant disease Growth hormone deficient children with overt diabetes mellitus (fasting blood glucose more than 126mg/dl)</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>